Abstract Issue

Volume 12 Issue 4 ( October-December ) 2023

Original Articles

Comparative assessment of the efficacy of methotrexate with apremilast to methotrexate alone in moderate to severe cases of chronic plaque psoriasis
Dr. Rakesh Kumar Meena, Dr. Somya Singhal, Dr. Sreya Todi, Dr. Purnima Raj

Background: Psoriasis is a chronic inflammatory systemic condition depicting a high relapse rate. The mainstream drugs for treating psoriasis in current times are phosphodiesterase type 4 inhibitor and- Apremilast and a dihydrofolate reductase inhibitor namely methotrexate. Aim: The present study was done to comparatively assess the efficacy of methotrexate with apremilast to methotrexate alone in moderate to severe cases of chronic plaque psoriasis. Methods: The present prospective comparative evaluation included 80 adult subjects with confirmed diagnosis of chronic plaque psoriasis. A comprehensive clinical and demographic evaluation was done in all subjects with performed structured proforma. Total study subjects were divided into 2 groups of 40 subjects each where Group I subjects were treated using combined oral methotrexate and Apremilast and Group II using Oral Apremilast only and were assessed at 4 and 12 weeks after investigations when required. Results: In the present study, 55% (n=44) of subjects were from the age range of 31-50 years and comorbidities including hypertension, diabetes, and others were reported in 27.5% (n=22) subjects. The PASI scores from Group I were lower compared to Group II at all first, second, and third follow-ups. A significantly higher reduction in mean PASI scores was seen in Group I at the follow-ups with 89% improvement at 12 weeks follow-up. Conclusions: The present study concludes that multidrug therapy with combined Apremilast and Methotrexate has better efficacy in treating chronic plaque psoriasis in comparison to methotrexate alone.

 
Html View | Download PDF | Current Issue

Get In Touch

IJLBPR

322 Parlount Road Slough Berkshire SL3 8AX, UK

ijlbpr@gmail.com

Submit Article

© IJLBPR. All Rights Reserved.